A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Effect of Mild, Moderate and Severe Renal Impairment on the Pharmacokinetics of YM178

The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.

Inclusion Criteria:

• good health other than renal impairment
• body mass index (BMI) between 18 and 40 kg/m2

Exclusion Criteria:

• subject with renal impairment has not been on stable dose of concomitant medication for at least 2 weeks
• subject has liver enzyme abnormalities